Sun Pharmaceutical Industries expects high single-digit top line growth in FY24 with total revenue at Rs 48,497 crore, led by Managing Director Dilip Shanghvi. The firm anticipates similar growth in FY25 with investments in product launches and R&D activities ..read more

A Pfizer lung cancer drug has been shown to greatly reduce tumor progression and improve survival outcomes for people in the advanced stages of a rare form of the disease, according to trial results published Friday ..read more

Aurobindo Pharma's subsidiary, TheraNym Biologics Pvt Ltd, has signed a master service agreement with Merck Sharpe & Dohme Singapore for contract manufacturing of biologicals. The agreement, effective May 31, 2024, will see TheraNym contract manufacturing biologicals for domestic and international markets. TheraNym will invest Rs 1,000 crore in a biologics manufacturing facility in Telangana ..read more

The pharmaceuticals market in India is witnessing significant growth, with anti-diabetic drugs leading the way with over ₹155 crore in value growth among new brands launched in the past year. The respiratory segment and vitamin/mineral/nutrient segment followed closely behind. The anti-diabetes market has grown rapidly in the last five years, driven by factors like the increasing number of patients and the launch of new drug combinations. The pharmaceutical market rebounded in April 2024, with chronic segments showing faster growth compared to acute segments ..read more

India's pharmaceutical exports are projected to grow nearly 11% this fiscal year, up from about 10% last year, driven by the U.S. and UK markets, according to Pharmexcil. Exports are expected to surpass $31 billion, rising from nearly $28 billion in fiscal 2024, despite quality concerns following cough syrup-linked deaths ..read more

Pharmaceutical companies asked to submit undertaking to government for compliance with UCPMP 2024 by June 30, as per DoP circular dated May 28 ..read more

ChrysCapital, led by MD Kshitij Sheth, aims to acquire Indian companies in the formulation business with potential valuations of $200 million-$500 million, focusing on growth and eventual public listings ..read more

In a significant development, a five-member expert committee has been appointed to assess the feasibility of allowing the manufacturing of nutraceuticals within drug manufacturing facilities in India. This decision comes after the country's drug regulator had previously warned of taking action against those violating regulations by producing supplements and drugs in the same facility ..read more

Indian drugmakers, such as Dr Reddy's, Cipla, and Sun Pharma, are projected to maintain revenue growth in fiscal 2025, driven by drug shortages in the U.S. market. With 233 drugs in short supply, Indian companies are poised to benefit from the challenges faced by U.S.-based generic pharma manufacturers, leading to improved financial performance and increased market share in therapeutic categories ..read more

The reason for the popularity of PPIs among doctors and patients is not tough to gauge. With unhealthy lifestyles and dietary habits, acidity is common among Indians. While many brands of PPIs are sold almost over-the-counter, Pan, Pantop, Omez and Rablet fly off the chemist’s shelves. Doctors warn that overuse of these drugs can have a slow and debilitating impact ..read more